Obesity Drug Approval Needs A New Paradigm, Stakeholder Group Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Group convened by George Washington University School of Public Health and Health Services recommends a “patient-centered” approach to reviewing obesity drugs that includes assessing the therapies for their risks and benefits for obese individuals who are healthy, have risk factors for co-morbidities or impairments to daily feeling or functioning, or are already sick.
You may also be interested in...
“The Pink Sheet” DAILY’s Most Popular Stories Last Week
Obesity and diabetes drug development and market issues drew the most attention from readers.
Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave
During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.
REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.